Challenges Ahead for Next Year's Flu Vaccine

The withdrawal of the United States from the World Health Organization presents significant challenges for American scientists in tracking and combating flu and other diseases. This could have serious repercussions for developing an effective flu vaccine for 2025.

Diminished Global Insights Affect CDC Operations

Within the CDC laboratory in Atlanta, a researcher dons a secure sealed suit to handle flu samples. Normally, the U.S. CDC receives thousands of these samples from flu patients worldwide each year. These samples play a fundamental role in monitoring virus changes and aid the WHO in designing the annual flu vaccine.

However, this steady supply of data has nearly stopped, according to former CDC official Demetre Daskalakis. From February to July, only 427 samples were received, marking a 60% reduction compared to the previous year, with contributions from just 12 countries.

The significant decrease in sample submissions complicates the CDC's success in developing accurate vaccines, says ex-director Daniel Jernigan of the CDC's National Center for Emerging and Zoonotic Infectious Diseases.

A Fragmented Global Perspective

The global network of WHO collaborating centers, which includes the CDC, processes samples from over 150 nations' influenza centers. The year has seen a downturn in these samples, according to WHO representative Maria Van Kerkhove.

WHO traditionally finances the global transportation of these samples. However, following President Trump's announcement of the U.S. withdrawal, WHO has faced a significant budget shortfall, impacting this crucial funding and necessitating alternative funding solutions.

Kanta Subbarao, a flu expert from Laval University, cautions that fewer samples will weaken flu surveillance, hindering future vaccine formulation efforts.

Every February and September, experts from these WHO centers convene to identify the flu strains for vaccines targeting the northern and southern hemisphere flu cycles.

“Since we can’t precisely predict which virus will prevail, multiple strains are included to safeguard against possible threats,” explains Subbarao.

Less data makes this process more precarious, despite the advanced capabilities of labs like the CDC.

Implications for Pandemic Preparedness

The shortage of samples constrains critical analysis, as indicated by Arnold Monto, an epidemiologist at the University of Michigan. Moreover, the CDC's diminished role post-WHO withdrawal may leave the U.S. vulnerable to future flu pandemics, says Daskalakis.

Typically, the CDC welcomes virus samples from a worldwide network, receiving “candidate vaccine viruses” that aid mass flu shot production.

Yet by August, the CDC had obtained hardly any, which could seriously impact readiness for potential flu outbreaks.

The CDC's efforts in tracking other critical pathogens are similarly compromised, potentially delaying the identification of significant viral variants.

“The detection system excels with lots of data,” emphasizes Daskalakis. “Without it, crucial discoveries take longer.”

Reflecting on the COVID pandemic, Daskalakis warns of the deadly consequences of delayed responses and reduced international cooperation, predicting similar outcomes if the U.S. continues this path.